Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 149-153

  Mani, Sridhar ^a   Poo, Wen Jen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic response modifier; Gamma interferon; Renal cell carcinoma

Indexed keywords

GAMMA INTERFERON; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FATIGUE; FEMALE; FEVER; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; LEUKOPENIA; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NAUSEA; REMISSION INDUCTION; SURVIVAL RATE; VOMITING;

EID: 0029873399     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00012     Document Type: Article

References (26)

1. Harris DT. Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 1984;10:422-30.
2. Von Roemeling R, Rabatin JT, Fraley EE, et al. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. J Urol 1988;2:259-62.
3. Lotze MT, Rosenberg SA. Interleukin-2: clinical applications. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:159-77.
4. Muss HB. Renal cell carcinoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:298-310.
5. Buzaid AC, Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol 1989;16:12-19.
6. Rinehart J, Malspeis L, Young D, et al. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res 1986;46:5364-7.
7. Geboers ADH, DeMulder PHM, Debruyne FMJ, et al. Alpha and gamma interferon in the treatment of advanced renal cell carcinoma. Semin Surg Oncol 1988;4:191-4.
8. Quesada JR, Evans L, Saks SR, et al. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J Biol Response Mod 1988;7:234-9.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;41:207-14.
10. Gutterman JU, Rosenblum MG, Rios A, Pritsche H, Quesada JR. Pharmacokinetic study of partially pure r-interferon in cancer patients. Cancer Res 1984;44:4164-71.
11. Kurzrock R, Talpaz M, Gutterman JU. Interferons - alpha, beta, gamma: basic principles and preclinical studies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:264.
12. Otto U, Conrad S, Schneider AW, Klosterhalfen K. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Arzneimittelforschung 1988;38:1658-60.
13. Foon K, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon in the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988;7:540-5.
14. Rinehart JJ, Malspeis L, Young D, Neidhart JA. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J Biol Response Mod 1986;5:300-8.
15. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 1987;6:20-7.
16. Bruntsch U, DeMulder PHM, Ten Bokkel Huinink WW, et al. Phase II study of recombinant human interferon-gamma in metastatic renal Cell Carcinoma. J Biol Response Mod 1990;9: 335-8.
17. Ota K. Phase I-II study of recombinant human gamma interferon (KW2202) in cancer patients. J Interferon Res 1986;6(suppl 1): 52-4.
18. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Cancer 1987;60:929-33.
19. Kuebler JP, Goodman PJ, Brown TD, et al. Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study. Invest New Drugs 1990;8:307-9.
20. Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989;7:1875-84.
21. Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 1988;139:251-5.
22. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 1994;152:841-5.
23. Escudier B, Farace F, Angevin E, et al. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. Eur J Cancer 1993;29a:724-8.
24. Bergmann L, Fenchel K, Weidmann E, et al. Daily alternating administration of high-dose alpha-interferon 2b and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 1993;72:1733-42.
25. Otto U, Schneider A, Denkhaus H, Conrad S. Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies. Onkologie 1988;11:185-91.
26. Baars JW, Wagstaff J, Van Groeningen CJ, et al. Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement [Letter]. J Natl Cancer Inst 1993;85:410-1.